Kivizidiale

Timolol, the active ingredient in Kivizidiale, is a beta blocker/prostaglandin analog combination presented as a eye drops for ocular use. It treats primary open-angle glaucoma and ocular hypertension.\n\nGNH India supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale is indicated for conditions involving elevated intra‑ocular pressure within the glaucoma and ocular hypertension disease family.\n\nPrimary open-angle glaucoma: reduces intra‑ocular pressure to slow optic nerve damage.\nOcular hypertension: lowers intra‑ocular pressure to prevent progression to glaucoma.

Kivizidiale may cause ocular and systemic adverse reactions.\n\nCommon Side Effects:\n- Eye irritation or burning sensation\n- Transient blurred vision\n- Conjunctival hyperemia\n- Increased eyelash growth\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (e.g., angio‑edema)\n- Bronchospasm or worsening asthma\n- Marked bradycardia or systemic hypotension

Before prescribing Kivizidiale, clinicians should consider several safety aspects.\n\nAssess cardiovascular status: evaluate patients with severe bradycardia or heart block.\nMonitor respiratory conditions: use caution in individuals with asthma or COPD.\nCheck for sulfonamide allergy: avoid if known hypersensitivity exists.\nAvoid use in patients with narrow-angle glaucoma.\nPregnancy and lactation: safety not established; use only if benefit outweighs risk.\nStore at room temperature: keep in original container, protect from light and moisture.

Kivizidiale can interact with other medicines, requiring attention to potential additive effects.\n\nMajor Interactions (Avoid):\n- Non‑selective beta‑blockers (e.g., propranolol): risk of additive bradycardia or hypotension.\n- Other intra‑ocular pressure‑lowering agents (e.g., apraclonidine): may cause excessive ocular hypotension.\n- Sympathomimetic eye drops (e.g., epinephrine): may diminish timolol efficacy.\n\nModerate Interactions (Monitor Closely):\n- Systemic carbonic anhydrase inhibitors: possible additive IOP reduction.\n- Anticholinergic eye drops: may affect ocular surface tolerance.\n- MAO inhibitors: monitor for systemic cardiovascular effects.